0.60p
0.00%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Genincode
Its shares trade on LSE under the ticker GENI.L. It has been listed since 22 July 2021. In the fiscal year to 31 December 2025, it reported revenue of £3.1m and a net loss of £5.7m. At that date it held total assets of £2.4m and shareholders' equity of £124,000.
GENinCode Plc engages in the genetic risk assessment of cardiovascular disease. The company is headquartered in Oxford, Oxfordshire. The company went IPO on 2021-07-22. The firm is engaged in the risk assessment, prediction, and prevention of cardiovascular disease (CVD). Its tests include Cardio Incode, Lipid Incode, Sudd Incode, Roca Test, Thrombo and Thrombo Incode Reproductive Health. The firm's product portfolio draws on advanced genomic precision testing using polygenic (multiple genes) technology, molecular testing, genotyping, sequencing, and AI bioinformatics to risk assess patient DNA. Its predictive technology provides patients and physicians with global preventative care and treatment strategies. Its products combine genetic and clinical data to risk-assess patients and provide healthcare practitioners with advanced clinical information to evaluate and predict the onset of cardiovascular disease. The Company’s wholly owned subsidiaries include GENinCode S.L.U. and GENinCode U.S. INC.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 22 Jul 2021
- Employees
- 28
- Website
- genincode.com ↗
Leadership
Pay as last reported
- Mr. William RhodesIndependent Non-Executive Chairman of the Board£58,793
- Mr. Matthew WallsChief Executive Officer, Executive Director, since 2018£297,046
- Mr. Paul FoulgerChief Financial Officer, Executive Director, Company Secretary, since 2021£181,089
- Mr. Jordi GilberteChief Operating Officer, Executive Director, since 2018£170,942
- Mr. Felix FruehIndependent Non-Executive Director£38,218
- Prof. Huon GrayIndependent Non-Executive Director£38,332
- Mr. Sergio OliveroIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Genincode PLC employs 28 full-time employees in Oxford, GB, focusing on genetic risk assessment.
- Cardio Incode and Lipid Incode are key products using polygenic technology for cardiovascular disease prediction.
- GENinCode S.L.U. and GENinCode U.S. INC. support global market expansion within Health Care.
Weaknesses
- The company has only 28 employees, limiting scalability and resource allocation.
- Genincode PLC's IPO was on 22 July 2021, indicating a relatively new market presence.
- The firm's product portfolio relies heavily on genomic precision testing technology.
Opportunities
- The Health Care sector offers growth potential for genetic risk assessment solutions like Cardio Incode.
- Expanding into the U.S. market through GENinCode U.S. INC. presents new opportunities.
- Global preventative care strategies can leverage Genincode's AI bioinformatics technology.
Threats
- Cardiovascular disease risk assessment faces competition from established healthcare providers.
- The Health Care industry requires strict regulatory compliance, increasing operational complexity.
- Genomic testing technology may face ethical concerns regarding patient data privacy.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.